Risk Prediction for Rapidly Progressive Interstitial Lung Disease in Anti-MDA5-Positive Dermatomyositis: The CRAFT Model

por Guo, Jinqiang, Mei, Chunli, Yu, Qi, Huang, Anbin
Publicado 2023

Smart system of disease management for patient follow-up and medication refill during the COVID-19 epidemic period: a multicentre retrospective cohort study

por Dong, Lingli, Huang, Anbin, Zhang, Shengtao, Yu, Yikai, li, Shouxin, Shen, Lingxun, Yang, Huiqin, Li, Huiling, Tu, Shenghao, Xiao, Fei
Publicado 2020

COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study

por Zhong, Jixin, Shen, Guifen, Yang, Huiqin, Huang, Anbin, Chen, Xiaoqi, Dong, Li, Wu, Bin, Zhang, Anbin, Su, Linchong, Hou, Xiaoqiang, Song, Shulin, Li, Huiling, Zhou, Wenyu, Zhou, Tao, Huang, Qin, Chu, Aichun, Braunstein, Zachary, Rao, Xiaoquan, Ye, Cong, Dong, Lingli
Publicado 2020

Attitudes toward COVID-19 Vaccination: A Survey of Chinese Patients with Rheumatic Diseases

por Yi, Zixi, Yao, Zhongqiang, Xu, Dan, Xu, Chuanhui, Fang, Wenqiang, Guo, Zhanfei, Wang, Yong, Huang, Jianlin, Li, Qin, Zhang, Hong, Huang, Anbin, Wu, Lijun, Wu, Zhenbiao, Guo, Huifang, Zhang, Fengxiao, Lu, Jing, Zhang, Zhenchun, Yu, Zhongming, Da, Zhanyun, Luo, Li, Wu, Bin, Wu, Henglian, Zeng, Lin, Mu, Rong
Publicado 2022

Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter,...

por Su, Jinmei, Li, Mengtao, He, Lan, Zhao, Dongbao, Wan, Weiguo, Liu, Yi, Xu, Jianhua, Xu, Jian, Liu, Huaxiang, Jiang, Lindi, Wu, Huaxiang, Zuo, Xiaoxia, Huang, Cibo, Liu, Xiumei, Li, Fen, Zhang, Zhiyi, Liu, Xiangyuan, Dong, Lingli, Li, Tianwang, Chen, Haiying, Li, Jingyang, He, Dongyi, Lu, Xin, Huang, Anbin, Tao, Yi, Wang, Yanyan, Zhang, Zhuoli, Wei, Wei, Li, Xiaofeng, Zeng, Xiaofeng
Publicado 2020

Changes in Efficacy Indicators for Adalimumab Biosimilar Candidate (HS016) for the Treatment of Active Ankylosing Spondylitis at Various Time Points

por Su, Jinmei, Li, Mengtao, He, Lan, Zhao, Dongbao, Wan, Weiguo, Liu, Yi, Xu, Jianhua, Xu, Jian, Liu, Huaxiang, Jiang, Lindi, Wu, Huaxiang, Zuo, Xiaoxia, Huang, Cibo, Liu, Xiumei, Li, Fen, Zhang, Zhiyi, Liu, Xiangyuan, Dong, Lingli, Li, Tianwang, Chen, Haiying, Li, Jingyang, He, Dongyi, Lu, Xin, Huang, Anbin, Tao, Yi, Wang, Yanyan, Zhang, Zhuoli, Wei, Wei, Li, Xiaofeng, Zeng, Xiaofeng
Publicado 2020

Evaluation of adalimumab biosimilar candidate (HS016) in Chinese patients with active ankylosing spondylitis based on a health survey: sub-analysis of a phase 3 study

por Su, Jinmei, Li, Mengtao, He, Lan, Zhao, Dongbao, Wan, Weiguo, Liu, Yi, Xu, Jianhua, Xu, Jian, Liu, Huaxiang, Jiang, Lindi, Wu, Huaxiang, Zuo, Xiaoxia, Huang, Cibo, Liu, Xiumei, Li, Fen, Zhang, Zhiyi, Liu, Xiangyuan, Dong, Lingli, Li, Tianwang, Chen, Haiying, Li, Jingyang, He, Dongyi, Lu, Xin, Huang, Anbin, Tao, Yi, Wang, Yanyan, Zhang, Zhuoli, Wei, Wei, Li, Xiaofeng, Zeng, Xiaofeng
Publicado 2021